Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Actinium Ac 225 Lintuzumab · SGN-33 AC-225

Radiopharmaceutical · Kills target cells, directed at CD33 antigen (CD33)

Phase 1 Most advanced trial (none active)
1 Registered trials

What is Actinium Ac 225 Lintuzumab?

Actinium Ac 225 lintuzumab is a radioimmunoconjugate in which the humanized monoclonal antibody lintuzumab carries the alpha-emitting radioisotope actinium Ac 225. The antibody binds CD33, a cell surface antigen overexpressed on myeloid leukemia cells, delivering a cytotoxic dose of alpha radiation to those cells. It is studied in leukemia and myelodysplastic syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SGN-33 AC-225
Drug type
Radiopharmaceutical
Targets
CD33 antigen (CD33)
Mechanism
Kills target cells, directed at CD33 antigen (CD33)
Pathways
alpha radiation-mediated cell killing
Therapy area
Oncology
In trials of
ATNM
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
V860J30J9N

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00672165 Phase 1 Leukemia Completed ATNM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

LeukemiaMyelodysplastic Syndrome

Other drugs acting on CD33

BI 836858 Phase 2/3 Lintuzumab Phase 1 Lintuzumab-Ac225 Phase 1/2

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.